NCT03939312

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

A Phase 3, Multicenter, Open-Label 40-week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 685 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Conditions

• Episodic Migraine

Interventions

Type	Name	Description
DRUG	Atogepant	Atogepant Tablets

Timeline

• Start date: 2019-05-06
• Primary completion: 2021-03-31
• Completion: 2021-03-31
• First posted: 2019-05-06
• Last updated: 2022-05-12
• Results posted: 2022-05-12

Locations

113 sites across 1 country: United States

Regulatory

• FDA-regulated drug study